menu
    • menu

    Company profile for PureTech Health

    NEW Drugs in Dev.: 8
    Evonik

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-01-12

    Virtual Booth

    Contact Supplier

    End-to-end drug development, specializing in high-potency softgels and liquids, providing global partners with a competitive advantage.

    Virtual Booth

    Contact Supplier

    Kewpie is your partner for Sodium Hyaluronate & Hyaluronic Acid// CEP, USDMF, KDMF & JDMF registered.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    At PureTech Health, we are harnessing the latest insights from human biology to develop new categories of medicine. PureTech Health is pioneering the development of therapeutics based on the crosstalk and biology of the brain-immune-gut axis.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    PureTech HealthUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    501 Boylston Street Boston, MA 02116
    Telephone
    Telephone
    617.482.2333
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://puretechhealth.com/
    Linkedin
    Linkedin
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Tides Asia

    Tides Asia

    Not Confirmed

    envelop Contact Supplier

    Tides Asia

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Puretech To Present At J.P. Morgan Healthcare Conference
    Puretech To Present At J.P. Morgan Healthcare Conference

    06 Jan 2026

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20260106445413/en/PureTech-to-Present-at-44th-Annual-J.P.-Morgan-Healthcare-Conference

    BUSINESSWIRE
    06 Jan 2026
    Share Share
    Puretech Appoints Robert Lyne As Chief Executive Officer
    Puretech Appoints Robert Lyne As Chief Executive Officer

    18 Dec 2025

    // PHARMIWEB

    https://www.pharmiweb.com/press-release/2025-12-18/puretech-appoints-robert-lyne-as-chief-executive-officer

    PHARMIWEB
    18 Dec 2025
    Share Share
    PureTech Gets Positive FDA EOP2 for LYT-100 in IPF
    PureTech Gets Positive FDA EOP2 for LYT-100 in IPF

    08 Dec 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20251207891734/en/PureTech-Announces-Successful-End-of-Phase-2-Meeting-with-FDA-for-Deupirfenidone-LYT-100-in-Idiopathic-Pulmonary-Fibrosis

    BUSINESSWIRE
    08 Dec 2025
    Share Share
    PureTech’s Gallop Oncology Reports Positive Ph1B Data For LYT-200
    PureTech’s Gallop Oncology Reports Positive Ph1B Data For LYT-200

    05 Dec 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20251205523069/en/PureTechs-Founded-Entity-Gallop-Oncology-Announces-Positive-Initial-Topline-Data-from-Phase-1b-Trial-of-LYT-200-in-RelapsedRefractory-Acute-Myeloid-Leukemia-and-High-Risk-Myelodysplastic-Syndrome

    BUSINESSWIRE
    05 Dec 2025
    Share Share
    Gallop Oncology To Unveil LYT-200 Phase 1B AML Trial Data at ASH
    Gallop Oncology To Unveil LYT-200 Phase 1B AML Trial Data at ASH

    03 Nov 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20251103719390/en/PureTechs-Founded-Entity-Gallop-Oncology-to-Present-New-Data-from-Ongoing-Phase-1b-Trial-of-LYT-200-in-RelapsedRefractory-Acute-Myeloid-Leukemia-AML-at-the-American-Society-of-Hematology-ASH-Annual-Meeting

    BUSINESSWIRE
    03 Nov 2025
    Share Share
    Puretech Shows Deupirfenidone Safety And Efficacy In Elderly IPF
    Puretech Shows Deupirfenidone Safety And Efficacy In Elderly IPF

    22 Oct 2025

    // PHARMIWEB

    https://www.pharmiweb.com/press-release/2025-10-22/puretech-presents-new-phase-2b-analyses-demonstrating-consistent-safety-and-efficacy-of-deupirfenidone-in-older-patients-with-idiopathic-pulmonary-fib

    PHARMIWEB
    22 Oct 2025
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search